Graph AI raises $3 Mn in seed round from Bessemer Venture Partners

Graph AI, a life sciences technology firm focused on pharmacovigilance and patient safety, has raised $3 million in a seed funding round led by Bessemer Venture Partners.

The proceeds will be used to expand its engineering team, accelerate product development, and grow its enterprise customer base globally.

Founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI operates in the $8 billion pharmacovigilance market, a regulatory process where pharmaceutical companies track and report adverse drug events (ADEs) throughout a drug’s lifecycle.

Pharma companies currently rely on manual data extraction and analysis across unstructured sources such as medical reports, call transcripts, legal filings, and literature. Graph AI’s flagship platform, Graph Safety, automates these workflows using AI and intelligent automation. 

It supports ADE case processing, signal detection, aggregate reporting, and compliance, reducing human intervention to only required regulatory steps.

Its system centralizes safety data and improves accuracy in medical reviews while maintaining audit readiness. Enterprise clients using the platform have reported significant efficiency gains and faster compliance cycles.

Graph AI’s team includes professionals with prior experience at Infosys, LTI Mindtree, ServiceNow, Google, and Cisco. It plans to build on its early customer traction across a pipeline of more than 7,000 marketed drugs as it scales operations.